These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 30045814)

  • 1. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
    Zhang Y; Nakano D; Guan Y; Hitomi H; Uemura A; Masaki T; Kobara H; Sugaya T; Nishiyama A
    Kidney Int; 2018 Sep; 94(3):524-535. PubMed ID: 30045814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis.
    Hirashima Y; Nakano T; Torisu K; Aihara S; Wakisaka M; Kitazono T
    Sci Rep; 2024 Sep; 14(1):20386. PubMed ID: 39223189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
    Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
    Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
    Aroor AR; Das NA; Carpenter AJ; Habibi J; Jia G; Ramirez-Perez FI; Martinez-Lemus L; Manrique-Acevedo CM; Hayden MR; Duta C; Nistala R; Mayoux E; Padilla J; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2018 Jul; 17(1):108. PubMed ID: 30060748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene deletion of the Na
    Nespoux J; Patel R; Hudkins KL; Huang W; Freeman B; Kim YC; Koepsell H; Alpers CE; Vallon V
    Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1201-F1210. PubMed ID: 30995111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Co-Transporter 2 Inhibitors Correct Metabolic Maladaptation of Proximal Tubular Epithelial Cells in High-Glucose Conditions.
    Shirakawa K; Sano M
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene knockout of the Na
    Nespoux J; Patel R; Zhang H; Huang W; Freeman B; Sanders PW; Kim YC; Vallon V
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1100-F1112. PubMed ID: 32116018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy.
    Bessho R; Takiyama Y; Takiyama T; Kitsunai H; Takeda Y; Sakagami H; Ota T
    Sci Rep; 2019 Oct; 9(1):14754. PubMed ID: 31611596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice.
    Zhang A; Nakano D; Kittikulsuth W; Yamashita Y; Nishiyama A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspase-3 Is a Pivotal Regulator of Microvascular Rarefaction and Renal Fibrosis after Ischemia-Reperfusion Injury.
    Yang B; Lan S; Dieudé M; Sabo-Vatasescu JP; Karakeussian-Rimbaud A; Turgeon J; Qi S; Gunaratnam L; Patey N; Hébert MJ
    J Am Soc Nephrol; 2018 Jul; 29(7):1900-1916. PubMed ID: 29925521
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
    Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.
    Shi M; Flores B; Li P; Gillings N; McMillan KL; Ye J; Huang LJ; Sidhu SS; Zhong YP; Grompe MT; Streeter PR; Moe OW; Hu MC
    Am J Physiol Renal Physiol; 2018 Apr; 314(4):F501-F516. PubMed ID: 29187371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.
    Mori Y; Terasaki M; Hiromura M; Saito T; Kushima H; Koshibu M; Osaka N; Ohara M; Fukui T; Ohtaki H; Tsutomu H; Yamagishi SI
    Cardiovasc Diabetol; 2019 Oct; 18(1):143. PubMed ID: 31672147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies.
    Uchida S; Mitani A; Gunji E; Takahashi T; Yamamoto K
    J Pharmacol Sci; 2015 May; 128(1):54-7. PubMed ID: 26003086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucosamine-induced Sp1 O-GlcNAcylation ameliorates hypoxia-induced SGLT dysfunction in primary cultured renal proximal tubule cells.
    Suh HN; Lee YJ; Kim MO; Ryu JM; Han HJ
    J Cell Physiol; 2014 Oct; 229(10):1557-68. PubMed ID: 24591095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
    Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury.
    Jung YJ; Kim DH; Lee AS; Lee S; Kang KP; Lee SY; Jang KY; Sung MJ; Park SK; Kim W
    Am J Physiol Renal Physiol; 2009 Oct; 297(4):F952-60. PubMed ID: 19656917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
    Rezq S; Nasr AM; Shaheen A; Elshazly SM
    Basic Clin Pharmacol Toxicol; 2020 May; 126(5):413-423. PubMed ID: 31788938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.